U.S. FDA approves Takeda's lung cancer drug as 2nd-line treatment

April 28 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd said on Friday that the U.S. Food and Drug Administration approved its lung cancer drug, almost three months after the company acquired the drug's developer, Ariad Pharmaceuticals Inc.

by reutersCOMPANYNEWS via Endless Supplies .Biz - News